Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis
+Undoctored
Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis
Tuesday 13 June 2023, 01:29 PM

Pharmac will fund bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) from 1 July 2023
We're pleased to announce that from 1 July 2023 bedaquiline and linezolid will be funded for multi-drug resistant tuberculosis (MDR-TB) for both community and hospital use. This change will enable people with MDR-TB to be treated in the community where appropriate.